<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/ms2024-329</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-8628</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ДРУГИЕ ПРОБЛЕМЫ ЭНДОКРИНОЛОГИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>OTHER PROBLEMS OF ENDOCRINOLOGY</subject></subj-group></article-categories><title-group><article-title>Клинико-эпидемиологические характеристики пациентов с феохромоцитомой и забрюшинной параганглиомой</article-title><trans-title-group xml:lang="en"><trans-title>Clinical and epidemiological characteristics of patients with pheochromocytoma and retroperitoneal paraganglioma</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7840-4174</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Реброва</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Rebrova</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Реброва Дина Владимировна, к.м.н., врач-эндокринолог отделения эндокринной хирургии Клиники высоких медицинских технологий имени Н.И. Пирогова</p><p>190103, Санкт-Петербург, набережная реки Фонтанки, д. 154</p></bio><bio xml:lang="en"><p>Dina V. Rebrova, Cand. Sci. (Med.), Endocrinologist at the Endocrine Surgery Department</p><p>154, Fontanka River Emb., St Petersburg, 190103</p></bio><email xlink:type="simple">endocrinology@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9574-105X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ворохобина</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vorokhobina</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ворохобина Наталья Владимировна, д.м.н., профессор, заведующий кафедрой эндокринологии имени акад. В.Г. Баранова</p><p>195067, Санкт-Петербург, Пискаревский проспект, д. 47, павильон № 10</p></bio><bio xml:lang="en"><p>Natalia V. Vorokhobina, Dr. Sci. (Med.), Professor, Head of  the Department of  Endocrinology</p><p>47, Piskarovskiy Ave., St Petersburg, 195067</p></bio><email xlink:type="simple">natvorokh@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Санкт-Петербургский государственный университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Saint Petersburg State University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Северо-Западный государственный медицинский университет имени И.И. Мечникова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>North-Western State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>01</day><month>11</month><year>2024</year></pub-date><volume>0</volume><issue>16</issue><fpage>206</fpage><lpage>215</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Реброва Д.В., Ворохобина Н.В., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Реброва Д.В., Ворохобина Н.В.</copyright-holder><copyright-holder xml:lang="en">Rebrova D.V., Vorokhobina N.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/8628">https://www.med-sovet.pro/jour/article/view/8628</self-uri><abstract><sec><title>Введение</title><p>Введение. Феохромоцитома / параганглиома (ФЕО / ПГ) является редкой гормонально-активной опухолью. Несвоевременная ее диагностика может приводить к тяжелым, вплоть до фатальных, осложнениям. Это обуславливает необходимость ранней диагностики ФЕО / ПГ специалистами различных областей.</p></sec><sec><title>Цель</title><p>Цель. Подтвердить эпидемиологические характеристики ФЕО / ПГ, наиболее часто встречающихся симптомов в целом в группе ФЕО / ПГ и в подгруппах клинических форм; сформировать группу риска для проведения скрининга на ФЕО / ПГ.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В исследование включено 353 пациента, прооперированных в КВМТ имени Н.И. Пирогова СПбГУ с гистологически верифицированными ФЕО / ПГ. Клинические симптомы оценивались: а) ретроспективно, путем анализа жалоб и анамнеза из первичного осмотра в историях болезни при поступлении в стационар; б) как во всей группе в целом, так и в подгруппах клинических форм. Статистический анализ выполнен с помощью языка программирования Python 3.11 (Python Software Foundation, США). Гистограмма частот построена с помощью библиотеки Matplotlib 3.8.2.</p></sec><sec><title>Результаты</title><p>Результаты. ФЕО / ПГ наиболее часто встречается у женщин после 40 лет. Наиболее частые симптомы при ФЕО / ПГ: ощущение учащенного сердцебиения (55,95%), головная боль (41,07%), артериальная гипертензия (АГ) в виде гипертонических кризов (55,65%), постоянного повышения уровня АД (38,39%), эпизодов умеренного повышения АД (24,11%), потливость (30,65%), общая слабость и утомляемость (26,19%), приливы жара или озноба (24,11%). Данные симптомы сформированы в критерии для скрининга на ФЕО / ПГ. При бессимптомной клинической форме чаще встречается боль в пояснице (14%); при пароксизмальной – панические атаки (10%); при смешанной – жажда и сухость во рту (10%), а при постоянной – собственно постоянный характер АГ (100%).</p></sec><sec><title>Заключение</title><p>Заключение. В крупной выборке пациентов с редкой патологией выявлен наиболее характерный симптомокомплекс как для ФЕО / ПГ, так и для отдельных клинических форм. Сформирована группа риска для проведения скрининга на ФЕО / ПГ.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Pheochromocytoma/paraganglioma (PPGL) is a rare hormonally active tumor of chromaffin tissue. Delayed diagnosis of this disease can lead to severe, even fatal, complications. Surgical treatment of PPGL without the necessary preoperative preparation can cause intraoperative uncontrolled hemodynamic impairment. In addition, since 2017, PPGL has been recognized as a malignant tumor due to the presence of metastatic potential. All these factors determine the need for early diagnosis of PPGL, which is based, first of all, on knowledge of the clinical picture by specialists in various fields.</p></sec><sec><title>Aim</title><p>Aim. To check and confirm the epidemiological characteristics of PPGL as well as the most common clinical symptoms in the whole group of PPGL and in subgroups of clinical forms; to form a risk group for screening for PPGL.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. There were enrolled 353 patients in the study. These patients were operated on at the St. Petersburg State University Hospital in the period from 2010 to 2022 inclusive. All the patients were verified PPGL diagnosis histologically. Clinical symptoms were assessed: a) retrospectively, by analyzing complaints and anamnesis from the initial examination in medical histories upon admission to the hospital for surgical treatment b) both in the entire group as a whole and in subgroups of clinical forms (paroxysmal, constant, mixed, asymptomatic). Statistical analysis was performed using the Python 3.11 programming language (Python Software Foundation, USA). descriptive statistics of quantitative characteristics are presented in the form of medians, first and third quartiles in me format [q1; q3], categorical features – in the form of absolute and relative frequencies in the format n (%). the frequency histogram was constructed using the Matplotlib 3.8.2 library.</p></sec><sec><title>Results</title><p>Results. PPGL is most common in women over 40 years of age. The most common symptoms of PPGL are the following: a feeling of rapid heartbeat (55.95%), headache (41.07%), arterial hypertension (AH) in the form of hypertensive crises (55.65%), constant increase in blood pressure (38.39%), episodes of moderate increases in blood pressure (24.11%), sweating (30.65%), general weakness and fatigue (26.19%), hot flashes or chills (24.11%). These symptoms are formed into the criteria for screening for PPGL. In the asymptomatic clinical form – lower back pain is more common (14%); with paroxysmal – panic attacks (10%); with mixed – thirst and dry mouth (10%), and with constant form – the actual constant nature of hypertension (100%).</p></sec><sec><title>Conclusion</title><p>Conclusion. In a large sample of patients with a rare pathology, the most characteristic symptom complex was identified, characteristic of both PPGL and individual clinical forms. A risk group has been formed for screening for PPGL.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>феохромоцитома</kwd><kwd>параганглиома</kwd><kwd>клинические формы</kwd><kwd>клинические симптомы</kwd><kwd>скрининг</kwd></kwd-group><kwd-group xml:lang="en"><kwd>pheochromocytoma</kwd><kwd>paraganglioma</kwd><kwd>clinical forms</kwd><kwd>clinical symptoms</kwd><kwd>screening</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Мельниченко ГА, Трошина ЕА, Бельцевич ДГ, Кузнецов НС, Юкина МЮ. Феохромоцитома/параганглиома: клинические рекомендации. 2016. 34 с. Режим доступа: https://www.endocrincentr.ru/sites/default/files/specialists/science/clinic-recomendations/klinicheskie_rekomendacii._feohromocitoma-paraganglioma.pdf.</mixed-citation><mixed-citation xml:lang="en">Мельниченко ГА, Трошина ЕА, Бельцевич ДГ, Кузнецов НС, Юкина МЮ. Феохромоцитома/параганглиома: клинические рекомендации. 2016. 34 с. Режим доступа: https://www.endocrincentr.ru/sites/default/files/specialists/science/clinic-recomendations/klinicheskie_rekomendacii._feohromocitoma-paraganglioma.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Бельцевич ДГ, Трошина ЕА, Юкина МЮ. Феохромоцитома. Проблемы эндокринологии. 2010;56(1):63–71. https://doi.org/10.14341/probl201056163-71.</mixed-citation><mixed-citation xml:lang="en">Bel’tsevich D, Troshina E, Iukina M. Pheochromocytoma. Problemy Endokrinologii. 2010;56(1):63–71. (In Russ.) https://doi.org/10.14341/probl201056163-71.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Tevosian SG, Ghayee HK. Pheochromocytomas and Paragangliomas. Endocrinol Metab Clin North Am. 2019;48(4):727–750. https://doi.org/10.1016/j.ecl.2019.08.006.</mixed-citation><mixed-citation xml:lang="en">Tevosian SG, Ghayee HK. Pheochromocytomas and Paragangliomas. Endocrinol Metab Clin North Am. 2019;48(4):727–750. https://doi.org/10.1016/j.ecl.2019.08.006.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Реброва ДВ, Ворохобина НВ, Имянитов ЕН, Русаков ВФ, Краснов ЛМ, Слепцов ИВ и др. Клиническо-лабораторные особенности наследственных феохромоцитом и параганглиом. Проблемы эндокринологии. 2022;68(1):8–17. https://doi.org/10.14341/probl12834.</mixed-citation><mixed-citation xml:lang="en">Rebrova DV, Vorokhobina NV, Imyanitov EN, Rusakov VF, Krasnov LM, Sleptsov IV et al. Clinical and laboratory features of hereditary pheochromocytoma and paraganglioma. Problemy Endokrinologii. 2022;68(1):8–17. (In Russ.) https://doi.org/10.14341/probl12834.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Eid M, Foukal J, Sochorová D, Tuček Š, Starý K, Kala Z et al. Management of pheochromocytomas and paragangliomas: Review of current diagnosis and treatment options. Cancer Med. 2023;12(13):13942–13957. https://doi.org/10.1002/cam4.6010.</mixed-citation><mixed-citation xml:lang="en">Eid M, Foukal J, Sochorová D, Tuček Š, Starý K, Kala Z et al. Management of pheochromocytomas and paragangliomas: Review of current diagnosis and treatment options. Cancer Med. 2023;12(13):13942–13957. https://doi.org/10.1002/cam4.6010.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ku EJ, Kim KJ, Kim JH, Kim MK, Ahn CH, Lee KA et al. Diagnosis for Pheochromocytoma and Paraganglioma: A Joint Position Statement of the Korean Pheochromocytoma and Paraganglioma Task Force. Endocrinol Metab (Seoul). 2021;36(2):322–338. https://doi.org/10.3803/EnM.2020.908.</mixed-citation><mixed-citation xml:lang="en">Ku EJ, Kim KJ, Kim JH, Kim MK, Ahn CH, Lee KA et al. Diagnosis for Pheochromocytoma and Paraganglioma: A Joint Position Statement of the Korean Pheochromocytoma and Paraganglioma Task Force. Endocrinol Metab (Seoul). 2021;36(2):322–338. https://doi.org/10.3803/EnM.2020.908.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Garcia-Carbonero R, Matute Teresa F, Mercader-Cidoncha E, Mitjavila-Casanovas M, Robledo M, Tena I et al. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas. Clin Transl Oncol. 2021;23(10):1995–2019. https://doi.org/10.1007/s12094-021-02622-9.</mixed-citation><mixed-citation xml:lang="en">Garcia-Carbonero R, Matute Teresa F, Mercader-Cidoncha E, Mitjavila-Casanovas M, Robledo M, Tena I et al. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas. Clin Transl Oncol. 2021;23(10):1995–2019. https://doi.org/10.1007/s12094-021-02622-9.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Kiriakopoulos A, Giannakis P, Menenakos E. Pheochromocytoma: a changing perspective and current concepts. Ther Adv Endocrinol Metab. 2023;14:20420188231207544. https://doi.org/10.1177/20420188231207544.</mixed-citation><mixed-citation xml:lang="en">Kiriakopoulos A, Giannakis P, Menenakos E. Pheochromocytoma: a changing perspective and current concepts. Ther Adv Endocrinol Metab. 2023;14:20420188231207544. https://doi.org/10.1177/20420188231207544.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Farrugia FA, Charalampopoulos A. Pheochromocytoma. Endocr Regul. 2019;53(3):191–212. https://doi.org/10.2478/enr-2019-0020.</mixed-citation><mixed-citation xml:lang="en">Farrugia FA, Charalampopoulos A. Pheochromocytoma. Endocr Regul. 2019;53(3):191–212. https://doi.org/10.2478/enr-2019-0020.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Patel D, Phay JE, Yen TWF, Dickson PV, Wang TS, Garcia R et al. Update on Pheochromocytoma and Paraganglioma from the SSO Endocrine/Head and Neck Disease-Site Work Group. Part 1 of 2: Advances in Pathogenesis and Diagnosis of Pheochromocytoma and Paraganglioma. Ann Surg Oncol. 2020;27(5):1329–1337. https://doi.org/10.1245/s10434-020-08220-3.</mixed-citation><mixed-citation xml:lang="en">Patel D, Phay JE, Yen TWF, Dickson PV, Wang TS, Garcia R et al. Update on Pheochromocytoma and Paraganglioma from the SSO Endocrine/Head and Neck Disease-Site Work Group. Part 1 of 2: Advances in Pathogenesis and Diagnosis of Pheochromocytoma and Paraganglioma. Ann Surg Oncol. 2020;27(5):1329–1337. https://doi.org/10.1245/s10434-020-08220-3.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Бокерия ЛА, Абдулгасанов РА, Шогенов МА, Абдулгасанова МР. Современные методы диагностики и лечения параганглиом (феохромоцитом). Грудная и сердечно-сосудистая хирургия. 2019;61(6):475–84. https://doi.org/10.24022/0236-2791-2019-61-6-475-484.</mixed-citation><mixed-citation xml:lang="en">Bockeria LA, Abdulgasanov RA, Shogenov MA, Abdulgasanova MR. Modern methods of diagnosis and treatment of paraganglioma (pheochromocytoma). Russian Journal of Thoracic and Cardiovascular Surgery. 2019;61(6):475–84. (In Russ.) https://doi.org/10.24022/0236-2791-2019-61-6-475-484.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов ИИ, Кузнецов НС, Бельцевич ДГ, Куратев ЛВ. 40-летний опыт диагностики и лечения опухолей хромаффинной ткани. Проблемы эндокринологии. 2003;49(1):44–50. https://doi.org/10.14341/probl11442.</mixed-citation><mixed-citation xml:lang="en">Dedov II, Kuznetsov NS, Beltsevich DG, Kuratev LV. Forty-year experience in diagnosing and treating chromaffine tissue tumors. Problemy Endokrinologii. 2003;49(1):44–50. (In Russ.) https://doi.org/10.14341/probl11442.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Geroula A, Deutschbein T, Langton K, Masjkur J, Pamporaki C, Peitzsch C et al. Pheochromocytoma and paraganglioma: clinical feature-based disease probability in relation to catecholamine biochemistry and reason for disease suspicion. Eur J Endocrinol. 2019;181(4):409–420. https://doi.org/10.1530/EJE-19-0159.</mixed-citation><mixed-citation xml:lang="en">Geroula A, Deutschbein T, Langton K, Masjkur J, Pamporaki C, Peitzsch C et al. Pheochromocytoma and paraganglioma: clinical feature-based disease probability in relation to catecholamine biochemistry and reason for disease suspicion. Eur J Endocrinol. 2019;181(4):409–420. https://doi.org/10.1530/EJE-19-0159.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Aygun N, Uludag M. Pheochromocytoma and Paraganglioma: From Epidemiology to Clinical Findings. Sisli Etfal Hastan Tip Bul. 2020;54(2):159–168. https://doi.org/10.14744/SEMB.2020.18794.</mixed-citation><mixed-citation xml:lang="en">Aygun N, Uludag M. Pheochromocytoma and Paraganglioma: From Epidemiology to Clinical Findings. Sisli Etfal Hastan Tip Bul. 2020;54(2):159–168. https://doi.org/10.14744/SEMB.2020.18794.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Amar L, Pacak K, Steichen O, Akker S, Aylwin SJB, Baudin E et al. International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nat Rev Endocrinol. 2021;17(7):435–444. https://doi.org/10.1038/s41574-021-00492-3.</mixed-citation><mixed-citation xml:lang="en">Amar L, Pacak K, Steichen O, Akker S, Aylwin SJB, Baudin E et al. International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nat Rev Endocrinol. 2021;17(7):435–444. https://doi.org/10.1038/s41574-021-00492-3.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Spiro A, Usman A, Ajmal A, Hoang ND, Shakir MKM. Asymptomatic and Biochemically Silent Pheochromocytoma with Characteristic Findings on Imaging. Case Rep Endocrinol. 2020;2020:8847261. https://doi.org/10.1155/2020/8847261.</mixed-citation><mixed-citation xml:lang="en">Spiro A, Usman A, Ajmal A, Hoang ND, Shakir MKM. Asymptomatic and Biochemically Silent Pheochromocytoma with Characteristic Findings on Imaging. Case Rep Endocrinol. 2020;2020:8847261. https://doi.org/10.1155/2020/8847261.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Shah SK, Tiwari M, Acharya S, Shah A. Asymptomatic pheochromocytoma associated with MEN syndrome and subclinical Cushing’s syndrome. Int J Surg Case Rep. 2023;108:108408. https://doi.org/10.1016/j.ijscr.2023.108408.</mixed-citation><mixed-citation xml:lang="en">Shah SK, Tiwari M, Acharya S, Shah A. Asymptomatic pheochromocytoma associated with MEN syndrome and subclinical Cushing’s syndrome. Int J Surg Case Rep. 2023;108:108408. https://doi.org/10.1016/j.ijscr.2023.108408.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Nölting S, Bechmann N, Taieb D, Beuschlein F, Fassnacht M, Kroiss M et al. Personalized Management of Pheochromocytoma and Paraganglioma. Endocr Rev. 2022;43(2):199–239. https://doi.org/10.1210/endrev/bnab019.</mixed-citation><mixed-citation xml:lang="en">Nölting S, Bechmann N, Taieb D, Beuschlein F, Fassnacht M, Kroiss M et al. Personalized Management of Pheochromocytoma and Paraganglioma. Endocr Rev. 2022;43(2):199–239. https://doi.org/10.1210/endrev/bnab019.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Реброва ДВ, Русаков ВФ, Федоров ЕА, Краснов ЛМ, Ворохобина НВ, Шихмагомедов ШШ и др. Редкий случай феохромоцитомы с гиперсекрецией кальцитонина. Фарматека. 2021;(4):90–98. https://doi.org/10.18565/pharmateca.2021.4.90-98.</mixed-citation><mixed-citation xml:lang="en">Rebrova DV, Rusakov VF, Fedorov EA, Krasnov LM, Vorokhobina NV, Shikhmagomedov ShSh et al. Rare case of pheochromocytoma with calcitonin hypersecretion. Farmateka. 2021;(4):90–98. (In Russ.) https://doi.org/10.18565/pharmateca.2021.4.90-98.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Шафигуллина ЗР, Петрова ММ, Шустов СБ, Ворохобина НВ, Протащик ДВ, Лисицын АА, Великанова ЛИ. Случай сочетания АКТГ-эктопического синдрома Иценко-Кушинга и феохромоцитомы. Российский семейный врач. 2013;17(4):43–46. Режим доступа: https://cyberleninka.ru/article/n/sluchay-sochetaniya-aktg-ektopicheskogo-sindroma-itsenko-kushinga-ifeohromotsitomy.</mixed-citation><mixed-citation xml:lang="en">Shafigullina ZR, Petrova MM, Shustov SB, Vorokhobina NV, Protashchik DV, Lisitsin AA, Velikanova LI. A case of combination ACTH-ectopic Cushings syndrome and pheochromocytoma. Russian Family Doctor. 2013;17(4):43–46. (In Russ.) Available at: https://cyberleninka.ru/article/n/sluchaysochetaniya-aktg-ektopicheskogo-sindroma-itsenko-kushinga-ifeohromotsitomy.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Реброва ДВ, Григорова СИ, Ворохобина НВ, Згода ЕА, Новокшонов АЮ, Феофанова СГ и др. Редкий случай кортикотропин-продуцирующей феохромоцитомы в составе синдрома множественных эндокринных неоплазий 1 типа. Проблемы эндокринологии. 2023;69(5):55–64. https://doi.org/10.14341/probl13260.</mixed-citation><mixed-citation xml:lang="en">Rebrova DV, Grigorova SI, Vorokhobina NV, Zgoda EA, Novokshonov KYu, Feofanova SG et al. Corticotropin-producing pheochromocytoma in multiple endocrine neoplasia type 1. Problemy Endokrinologii. 2023;69(5):55–64. (In Russ.) https://doi.org/10.14341/probl13260.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Mete O, Asa SL, Gill AJ, Kimura N, Krijger R, Tischler A. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocr Pathol. 2022;33(1):90–114. https://doi.org/10.1007/s12022-022-09704-6.</mixed-citation><mixed-citation xml:lang="en">Mete O, Asa SL, Gill AJ, Kimura N, Krijger R, Tischler A. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocr Pathol. 2022;33(1):90–114. https://doi.org/10.1007/s12022-022-09704-6.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
